Roche's big China play; Merck bets on mRNA, again; Bluebird's gene therapy takes off; Better PhIII? At a fraction of the cost?; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
There were days in the past few weeks where it’s felt really quiet on the news front — but then there are still enough important developments that we can’t bear to look away. See if you’ve missed anything this week. And if the Endpoints Weekly has been helpful for you, do spread the word.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.